210 related articles for article (PubMed ID: 25164110)
1. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
Sonbol MB; Maurer MJ; Stenson MJ; Allmer C; LaPlant BR; Weiner GJ; Macon WR; Cerhan JR; Witzig TE; Gupta M
Am J Hematol; 2014 Dec; 89(12):E223-7. PubMed ID: 25164110
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
[TBL] [Abstract][Full Text] [Related]
3. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
[TBL] [Abstract][Full Text] [Related]
4. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
6. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
7. PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma.
Zhang X; Han Y; Nie Y; Jiang Y; Sui X; Ge X; Liu F; Zhang Y; Wang X
J Mol Med (Berl); 2023 May; 101(5):595-606. PubMed ID: 37126184
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
[TBL] [Abstract][Full Text] [Related]
9. Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?
Haydaroglu Sahin H
Medicine (Baltimore); 2019 Jul; 98(30):e16180. PubMed ID: 31348229
[TBL] [Abstract][Full Text] [Related]
10. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
Hashimoto Y; Yokohama A; Saitoh A; Nakahashi H; Toyama K; Mitsui T; Koiso H; Saitoh T; Handa H; Uchiumi H; Jinbo T; Murayama K; Matsumoto M; Sawamura M; Karasawa M; Murakami H; Hirato J; Nojima Y; Kojima M; Tsukamoto N
J Clin Exp Hematop; 2013; 53(3):197-205. PubMed ID: 24369221
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
[TBL] [Abstract][Full Text] [Related]
13. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
[TBL] [Abstract][Full Text] [Related]
14. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
17. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
18. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E; Dreyling M; Klapper W; Gisselbrecht C; van Hoof A; Kluin-Nelemans HC; Pfreundschuh M; Reiser M; Metzner B; Einsele H; Peter N; Jung W; Wörmann B; Ludwig WD; Dührsen U; Eimermacher H; Wandt H; Hasford J; Hiddemann W; Unterhalt M; ;
Blood; 2008 Jan; 111(2):558-65. PubMed ID: 17962512
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
20. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
